Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

Cancer Research
Martin L SosDaniel Rauh

Abstract

Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small molecules to improve progression-free survival of patients with EGFR-mutated lung cancers. Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clinical activity in patients with T790M-mutant tumors. In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors. A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines. Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFR(T790M) resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase. Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis. Our findings offer a mechanistic explanation for the limited efficacy of irreversible E...Continue Reading

References

Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Feb 24, 2007·Nature Reviews. Cancer·Sreenath V SharmaDaniel A Haber
May 15, 2007·Cancer Biology & Therapy·Yuki YuzaMatthew Meyerson
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kwok-Kin Wong
Jan 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Cai-Hong YunMichael J Eck
Mar 5, 2008·Bioorganic & Medicinal Chemistry·Anja MichalczykDaniel Rauh
Apr 17, 2008·Molecular Cancer Therapeutics·Nadia Godin-HeymannDaniel A Haber
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey A Engelman, Pasi A Jänne
May 20, 2009·The Journal of Clinical Investigation·Martin L SosRoman K Thomas
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Oct 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Martin L SosRoman K Thomas
Oct 22, 2009·Cell Cycle·Martin L Sos, Roman K Thomas

❮ Previous
Next ❯

Citations

Oct 31, 2013·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·R Buettner, C Heydt
Sep 22, 2010·Journal of Molecular Modeling·Dariusz Plewczynski
Jan 28, 2012·Journal of Medicinal Chemistry·Caterina CarmiMarco Mor
May 25, 2012·Journal of Medicinal Chemistry·Tjeerd Barf, Allard Kaptein
Jun 19, 2013·Journal of Medicinal Chemistry·André RichtersDaniel Rauh
Oct 23, 2010·Nature Reviews. Cancer·William Pao, Juliann Chmielecki
Sep 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Dziadziuszko, J Jassem
Aug 27, 2010·Current Opinion in Oncology·Igor Vivanco, Ingo K Mellinghoff
Sep 29, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johannes M HeuckmannRoman K Thomas
Jun 21, 2013·Cancer Management and Research·Hiroyasu KanedaIsamu Okamoto
Jul 11, 2013·Future Oncology·Hsiang-Fong KaoJames Chih-Hsin Yang
Mar 20, 2014·Naunyn-Schmiedeberg's Archives of Pharmacology·Helmout ModjtahediFlavio Solca
Oct 28, 2014·Expert Opinion on Drug Safety·Mauricio BurottoGeraldine O'Sullivan Coyne
Nov 18, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Shunsuke OkumuraYoshinobu Ohsaki
Feb 11, 2015·Clinica Chimica Acta; International Journal of Clinical Chemistry·Marc G DenisSandrine Théoleyre
Apr 24, 2012·Hematology/oncology Clinics of North America·Anish ThomasGiuseppe Giaccone
Nov 8, 2011·Clinics in Chest Medicine·Scott Gettinger, Thomas Lynch
Apr 5, 2011·Translational Oncology·Brendan D LooyengaGlen J Weiss
Nov 3, 2015·Journal of Structural Biology·Yuliana YosaatmadjaChristopher J Squire
Jul 7, 2011·International Journal of Cancer. Journal International Du Cancer·Mi Young ChaMaeng Sup Kim
Oct 13, 2015·Journal of Medicinal Chemistry·Robert HealdTimothy P Heffron
Jun 4, 2010·Biochemical Pharmacology·Takeshi YoshidaEric B Haura
Aug 15, 2015·Journal of Medicinal Chemistry·Julian EngelDaniel Rauh
Jan 7, 2014·Expert Opinion on Therapeutic Patents·Si-Ning Li, Huan-Qiu Li
Jul 16, 2013·Cancer Treatment Reviews·Francesco AgustoniMarina Chiara Garassino
Jul 19, 2016·Medicina clínica·Pilar Diz TaínAndrés García-Palomo
May 2, 2012·ACS Chemical Biology·Christian GrütterDaniel Rauh

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.